Company intelligence / Profile preview

Aquilus Pharmaceuticals

Winchester, Massachusetts, USAaquiluspharma.com ↗
Ownership
Private
Development stage
Other
01

Overview

Aquilus Pharmaceuticals has developed AQU-118—a dual MMP2/MMP9 inhibitor—as a first-in-class oral therapy targeting neurodegenerative diseases such as ALS and neuropathic pain. The compound has shown excellent safety profiles in animal models and completed all necessary preclinical studies. The company holds issued patents on composition of matter and method of use for multiple indications. Clinical trials are expected to commence soon with strong support from major grants including the NIH and ALS Association

Therapeutic areas
Neurology
Modalities
small molecules (specifically, proprietary matrix metalloproteinase [MMP] inhibitors)
Industry
Biotech
02

Drug pipeline

1 asset

AQU-118

Unknown
03

Partnerships

Funded by ALS Association Drug Development ProgramNational Institutes of Health (NIH)Department of Defense ALS Research Program; no major pharma partnerships disclosed yet

Beyond the preview

Go deeper on Aquilus Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aquilus Pharmaceuticals.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call